These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 16014752)

  • 1. Amphetamine treatment similar to that used in the treatment of adult attention-deficit/hyperactivity disorder damages dopaminergic nerve endings in the striatum of adult nonhuman primates.
    Ricaurte GA; Mechan AO; Yuan J; Hatzidimitriou G; Xie T; Mayne AH; McCann UD
    J Pharmacol Exp Ther; 2005 Oct; 315(1):91-8. PubMed ID: 16014752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on amphetamine neurotoxicity and its relevance to the treatment of ADHD.
    Advokat C
    J Atten Disord; 2007 Jul; 11(1):8-16. PubMed ID: 17606768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA; Pliszka SR
    Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
    Findling RL
    Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attention-deficit/hyperactivity disorder in adults: evidence-based recommendations for management.
    Rostain AL
    Postgrad Med; 2008 Sep; 120(3):27-38. PubMed ID: 18824823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ; Merkel RL; Moore M; Thorndike F; Muller C; Kovatchev B
    Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Alterations in the pattern of dopaminergic markers in attention-deficit/hyperactivity disorder].
    Díaz-Heijtz R; Mulas F; Forssberg H
    Rev Neurol; 2006 Feb; 42 Suppl 2():S19-23. PubMed ID: 16555214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
    Biederman J; Wigal SB; Spencer TJ; McGough JJ; Mays DA
    Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study.
    Spencer TJ; Abikoff HB; Connor DF; Biederman J; Pliszka SR; Boellner S; Read SC; Pratt R
    Clin Ther; 2006 Mar; 28(3):402-18. PubMed ID: 16750455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modafinil treatment of amphetamine abuse in adult ADHD.
    Mann N; Bitsios P
    J Psychopharmacol; 2009 Jun; 23(4):468-71. PubMed ID: 18562425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.
    Biederman J; Swanson JM; Wigal SB; Kratochvil CJ; Boellner SW; Earl CQ; Jiang J; Greenhill L
    Pediatrics; 2005 Dec; 116(6):e777-84. PubMed ID: 16322134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The consequences of attention-deficit/hyperactivity disorder in adults.
    Goodman DW
    J Psychiatr Pract; 2007 Sep; 13(5):318-27. PubMed ID: 17890980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modafinil as a treatment for Attention-Deficit/Hyperactivity Disorder in children and adolescents: a double blind, randomized clinical trial.
    Amiri S; Mohammadi MR; Mohammadi M; Nouroozinejad GH; Kahbazi M; Akhondzadeh S
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan; 32(1):145-9. PubMed ID: 17765380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopaminergic dysfunction in attention deficit hyperactivity disorder (ADHD), differences between pharmacologically treated and never treated young adults: a 3,4-dihdroxy-6-[18F]fluorophenyl-l-alanine PET study.
    Ludolph AG; Kassubek J; Schmeck K; Glaser C; Wunderlich A; Buck AK; Reske SN; Fegert JM; Mottaghy FM
    Neuroimage; 2008 Jul; 41(3):718-27. PubMed ID: 18424180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
    Biederman J; Mick E; Surman C; Doyle R; Hammerness P; Harpold T; Dunkel S; Dougherty M; Aleardi M; Spencer T
    Biol Psychiatry; 2006 May; 59(9):829-35. PubMed ID: 16373066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Catecholamine dysfunction in attention-deficit/hyperactivity disorder: an update.
    Prince J
    J Clin Psychopharmacol; 2008 Jun; 28(3 Suppl 2):S39-45. PubMed ID: 18480676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder.
    Wilens TE
    J Clin Psychopharmacol; 2008 Jun; 28(3 Suppl 2):S46-53. PubMed ID: 18480677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.